Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

PURPOSE Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO to abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT. METHODS We identified a prospective cohort of 462 women with disease-associated germline BRCA1/2 mutations at 13 medical centers to evaluate breast cancer risk after BPO with and without HRT. We determined the incidence of breast cancer in 155 women who had undergone BPO and in 307 women who had not undergone BPO on whom we had complete information on HRT use. Postoperative follow-up was 3.6 years. RESULTS Consistent with previous reports, BPO was significantly associated with breast cancer risk reduction overall (hazard ratio [HR] = 0.40; 95%CI, 0.18 to 0.92). Using mutation carriers without BPO or HRT as the referent group, HRT of any type after BPO did not significantly alter the reduction in breast cancer risk associated with BPO (HR = 0.37; 95% CI, 0.14 to 0.96). CONCLUSION Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA1/2 mutation carriers.

[1]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[2]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[3]  J. Satagopan,et al.  Risk of endometrial carcinoma associated with BRCA mutation. , 2001, Gynecologic oncology.

[4]  B. Karlan.  Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. , 2004, Gynecologic oncology.

[5]  B. Weber,et al.  Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. , 2004, Journal of Clinical Oncology.

[6]  G. Rennert,et al.  BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. , 2004, Gynecologic oncology.

[7]  E. Negri,et al.  Hysterectomy, Oophorectomy in Premenopause, and Risk of Breast Cancer , 1997, Obstetrics and gynecology.

[8]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[9]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[10]  D. Schaid,et al.  Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[12]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[13]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[14]  B. V. VON Schoultz,et al.  Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status. , 1993, Journal of psychosomatic obstetrics and gynaecology.

[15]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[16]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[17]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[18]  M. Pike,et al.  Hormonal chemoprevention of cancer in women , 1993, Science.

[19]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[20]  R. Hoover,et al.  Menstrual factors and risk of breast cancer. , 1988, Cancer investigation.

[21]  F. V. van Leeuwen,et al.  Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. , 2003, Journal of the National Cancer Institute.

[22]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[23]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[24]  S. Wacholder.  Bias in intervention studies that enroll patients from high-risk clinics. , 2004, Journal of the National Cancer Institute.

[25]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[26]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[27]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.